ACAD
ACADIA Pharmaceuticals Inc.
ACAD has a slight edge over UNH overall, supported by stronger valuation and stronger fundamentals.
UNH
UnitedHealth Group Incorporated
UNH has lower modeled downside risk, despite its lower overall score.
ACAD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
ACAD's revenue, profitability, cash flow and balance sheet are all currently healthy.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ACAD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 8.6x | $18.14 | — |
| Cheap | 9.8x | $20.70 | +14% |
| Fair | 16x | $33.30 | +84% |
| Forward | 17x | $18.14 | — |
| Expensive | 23x | $47.72 | +163% |
Historical ranges are pointers, not guarantees.
ACAD has the edge over UNH in the historical PE scenario, which offers more potential upside but is not a forecast.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ACAD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ACAD, with profitability improving. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ACAD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.05 | -50% |
| Q3 2026 | $2.12 | +37% |
| Q2 2026 | $2.23 | +68% |
| Q1 2026 | $2.21 | +61% |
| Q4 2025 | $2.30 | +69% |
| Q3 2025 | $1.55 | +99% |
| Q2 2025 | $1.33 | +639% |
| Q1 2025 | $1.37 | +$1.38 |
| Q4 2024 | $1.36 | +$1.74 |
ACAD has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
ACAD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $342.3M | +23% |
| Q2 2026 | $308M | +16% |
| Q1 2026 | $268.1M | +9.7% |
| Q4 2025 | $284M | +9.4% |
| Q3 2025 | $278.6M | +11% |
| Q2 2025 | $264.6M | +9.3% |
| Q1 2025 | $244.3M | +19% |
| Q4 2024 | $259.6M | +12% |
ACAD has the edge over UNH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | +8.1 points |
| Q2 2026 | 12% | 0 points |
| Q1 2026 | -1.7% | -9.6 points |
| Q4 2025 | 6.1% | -53 points |
| Q3 2025 | 13% | +0.2 points |
| Q2 2025 | 12% | -0.3 points |
| Q1 2025 | 7.9% | +0.5 points |
| Q4 2024 | 59% | +44 points |
ACAD has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
ACAD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $10.3M | -86% |
| Q1 2026 | $28.8M | +42% |
| Q4 2025 | -$52.7M | -232% |
| Q1 2025 | $20.3M | -30% |
| Q4 2024 | $39.9M | -53% |
| Q2 2024 | $25M | +205% |
| Q1 2024 | $29.1M | +$47M |
| Q4 2023 | $85.4M | +$109.2M |
ACAD has burned cash in most quarters: $82M over the past year, down 48% from the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over ACAD on cash generation, producing positive trailing cash flow while its opponent burns cash.
ACAD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +2.6M shares |
| 1 year | +2.8% | +4.8M shares |
| 3 years | +8.8% | +14.2M shares |
| 5 years | +13% | +20.1M shares |
ACAD has 175M diluted shares, up 2.8% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over ACAD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ACAD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.4x | Net Cash |
| Q2 2026 | -3.9x | Net Cash |
| Q1 2026 | -3.0x | Net Cash |
| Q4 2025 | -1.5x | Net Cash |
| Q3 2025 | -1.0x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -0.9x | Net Cash |
| Q4 2024 | -1.3x | Net Cash |
ACAD has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ACAD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.7 | Neutral |
| Stochastic | 18.4 | Oversold |
ACAD's weekly RSI is 35 (neutral) and its Stochastic is 18 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ACAD PE vs Healthcare Sector
| Metric | ACAD | Sector median | Relative |
|---|---|---|---|
| PE | 8.6x | 26x | 67% below |
| PE % | 0 | 29 | 29 pts below |
ACAD has the edge over UNH on valuation relative to its sector.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
ACAD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.9 | 8.8% below |
| 20 week MA | $24.4 | 26% below |
| 50 week MA | $23.8 | 24% below |
| 100 week MA | $22.2 | 18% below |
| 200 week MA | $21.6 | 16% below |
ACAD is in a downtrend: it's below all five of its weekly moving averages, and 16% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over ACAD on trend strength, trading above more of its moving averages.
ACAD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.0 | $55.0 | +25% |
| 2021 | $55.0 | $24.3 | -56% |
| 2022 | $24.3 | $15.5 | -36% |
| 2023 | $15.5 | $31.3 | +102% |
| 2024 | $31.3 | $17.0 | -46% |
| 2025 | $17.0 | $27.6 | +63% |
| 2026 YTD | $27.6 | $18.1 | -34% |
ACAD's yearly returns have swung widely, from +102% in 2023 to −56% in 2021. It's down 34% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over ACAD on returns for 2026, with the stronger performance.